Semler Scientific, a company known for its innovative approach to healthcare technology, has made a significant investment in Bitcoin. The company recently announced that it has increased its Bitcoin holdings to 1,273 tokens, worth approximately $114 million at the current price of Bitcoin, which is close to $90,000 per token.
This increase in holdings was the result of Semler’s recent purchase of 215 Bitcoin for $17.7 million, with an average price of $82,502 per Bitcoin. This purchase was funded in part by share sales under Semler’s at-the-market program, totaling $21.5 million to date. In total, Semler has spent $88.7 million on Bitcoin, with an average price of $69,682 per Bitcoin.
One interesting metric that Semler has adopted is “Bitcoin Yield,” a key performance indicator developed by MicroStrategy. This metric measures how well a company acquires Bitcoin in a way that benefits shareholders. Semler reported a BTC Yield of 37.3% since implementing its Bitcoin treasury strategy in the second quarter of the year, demonstrating significant Bitcoin accretion for stakeholders.
Semler’s announcement comes amidst a flurry of corporate Bitcoin purchases, with companies like Metaplanet, Marathon Digital, and MicroStrategy also making significant moves in the cryptocurrency space. Semler’s stock price has responded positively to this news, rising by 2.4% in premarket trading and increasing by 33% since the company began investing in Bitcoin last summer.
As a media outlet focused on the cryptocurrency industry, CoinDesk maintains strict editorial policies to ensure integrity, editorial independence, and freedom from bias in its publications. James, a senior analyst at CoinDesk, specializes in Bitcoin and the macro environment, using on-chain analytics to understand market trends and investor behavior.
Overall, Semler Scientific’s decision to increase its Bitcoin holdings reflects a growing trend among companies to diversify their treasury reserves with digital assets. With Bitcoin’s price hitting new highs, more businesses may follow suit in the coming months.
